HUM-MOLGEN events: CHI's Third Annual PHARMACOGENOMICS

HUM-MOLGEN -> Events -> Meetings and Conferences

September 21, 2001

Cambridge Healthtech Institute, Cambridge Marriott, Cambridge, Massachusetts
New Dates: October 10-11, 2001

CHI's Third Annual PHARMACOGENOMICS

The ability to predict a drug response will have a substantial impact on drug marketing practices and may lead to a shakeup of the industry on a general scale. Mass customization-whether a dream come true or an unpleasant fait accompli-will affect pharmaceutical companies from top to bottom. Concomitantly, as our giant healthcare system slowly awakens to the miraculous insights biotechnology is capable of providing, physicians will be coerced away from their old illegible ways into a future of accurate, secured prescriptions. This meeting brings together leaders in the fields of genomics, medicine, and pharmaceutical development.

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

Keynote Presentation

Dr. Klaus Lindpaintner, F. Hoffmann-La Roche AG

Session Chairs

Dr. Claire Allan, GlaxoSmithKline
Dr. Felix Frueh, Georgetown University
Dr. Scott Weiss, Harvard Medical School and Brigham and Women's Hospital

Additional Speakers

Dr. Lynn Doucette-Stamm, Genome Therapeutics Corporation
Dr. Paz Einat, Quark Biotech (U.S.) and QBI Enterprises
Dr. David Gurwitz, Tel Aviv University
Dr. Eugueni Krynetski, St. Jude Children's Research Hospital
Dr. Roy Pettipher, Oxagen Limited
Dr. Steve Ryan, AstraZeneca
Dr. Kenneth Thummel, University of Washington
Dr. Daniel Tuse, Large Scale Biology Corporation
Dr William Wardell, President, Wardell Associates International
Suzin Webb, Pfizer Global Research and Development
Dr. Patricia Weber, Schering-Plough Corporation
Dr. Ma-Li Wong, University of California, Los Angeles

Deadline for Abstracts:

August 10, 2001

Registration:

http://www.chidb.com/2001/gvr/gvr_form.htm

E-mail:

fvargus@healthtech.com

Posted by:

Frederick Vargus

Host:

wks253.healthtech.com